SynthesisInternational urology and nephrology2026
The efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer: a meta-analysis based on subgroups and reconstructed individual patient data.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic hormone-sensitive prostate cancer (mHSPC) represents a critical stage in prostate cancer management. Two pivotal phase III clinical trials have demonstrated survival benefit with enzalutamide in mHSPC. This meta-analysis aims to evaluate the efficacy and safety of enzalutamide based on subgroup analyses and reconstructed individual patient-level data.
methodsA comprehensive literature search was conducted using PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. The primary outcome was overall survival (OS), while the secondary outcomes included prostate-specific antigen progression-free survival (pPFS), radiographic progression-free survival (rPFS), and adverse events (AEs). The risk ratios (RR) with 95% confidence intervals (CI) was selected as the effect size. Cochran's Q statistic was used to assess the subgroup differences. Survival analysis was performed using Cox hazards model based on the reconstructed individual patient data (IPD). I
resultsThe data of 2275 patients were analyzed eventually. Enzalutamide reduced the risk of death by 33% compared to the control. Specifically, enzalutamide reduced the risk of death to 0.64 and 0.84 in subgroups of low and high disease volume, with significant subgroup differences (P = 0.0346). Meanwhile, the risk of death in enzalutamide group was 0.73 among patients without visceral metastases, and 1.06 among those with visceral metastases, indicating significant subgroup differences (P = 0.0124). For geographical regions, Gleason scores, performance status, and docetaxel use, enzalutamide showed consistent effectiveness across all subgroups. Moreover, the risk of grade 3-4 AEs in the enzalutamide group was 1.44 compared to control. No significant heterogeneity was observed.
conclusionsEnzalutamide improves OS, pPFS, and rPFS in patients with mHSPC, and offers greater OS benefit for patients with low disease volume and no visceral metastases. Further investigation should validate these findings in real-world setting, and explore the long-term effect of enzalutamide or more combination regimens of enzalutamide plus other agents.
Indexed as
Identifiers
40660075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.